Replies to post #38888 on DNAprint Genomics (DNAG)

[frogdreaming]

Arch, A very important statement.

I like this part best.

The FDA approval covers those patients with particular genetic mutation on one chromosome that results in the inability of the bone marrow to produce enough normal red blood cells and blood-clotting platelets. Patients with this type of MDS require periodic blood and platelet transfusions and treatment with antibiotics for infections to remain well.

Did you notice how the FDA approval covers, (and no doubt, requires) both the mutation and the specific physiological discrepency related to that mutation?

regards,
frog